Top

Published in:

Open Access 01-01-2015 | Review Article

⁶⁸Gallium- and ⁹⁰Yttrium-/¹⁷⁷Lutetium: “theranostic twins” for diagnosis and treatment of NETs

Authors: Rudolf A. Werner, Christina Bluemel, Martin S. Allen-Auerbach, Takahiro Higuchi, Ken Herrmann

Published in: Annals of Nuclear Medicine | Issue 1/2015

Abstract

Abundant expression of somatostatin receptors (SSTR) is frequently identified in differentiated neuroendocrine tumors and may serve as potential target for diagnostic imaging and treatment. This article discusses the “theranostic approach” of SSTR-targeting compounds including an overview of its role for diagnosis, staging and restaging, discussing its way to being established in clinical routine, and giving an outlook about further potentially relevant developments.

Seidlin SM, Marinelli LD, Oshry E. Radioactive iodine therapy; effect on functioning metastases of adenocarcinoma of the thyroid. J Am Med Assoc. 1946;132:838–47.PubMedCrossRef

Pahaut JE. Use of radiostrontium (Sr89) in the treatment of cancer. Govaerts J J Radiol Electrol Arch Electr Medicale. 1956;37:164–9.

Pecher C. Biological investigations with radioactive calcium and strontium: preliminary report on the use of radioactive strontium in the treatment of bone cancer. Univ Calif Publ Pharmacol. 1942;11:117–49.

Treuner J, Feine U, Niethammer D, Muller-Schaumburg W, Meinke J, Eibach E, et al. Scintigraphic imaging of neuroblastoma with [131-I]iodobenzylguanidine. Lancet. 1984;1:333–4.PubMedCrossRef

Decarolis B, Schneider C, Hero B, Simon T, Volland R, Roels F, et al. Iodine-123 metaiodobenzylguanidine scintigraphy scoring allows prediction of outcome in patients with stage 4 neuroblastoma: results of the Cologne interscore comparison study. J Clin Oncol. 2013;31:944–51.PubMedCrossRef

Aktolun C, Castellani MR, Bombardieri E. Diagnostic and therapeutic use of MIBG in pheochromocytoma and paraganglioma. Q J Nucl Med Mol Imaging. 2013;57:109–11.PubMed

Kreissl MC, Schirbel A, Fassnacht M, Haenscheid H, Verburg FA, Bock S, et al. [¹²³I]Iodometomidate imaging in adrenocortical carcinoma. J Clin Endocrinol Metab. 2013;98:2755–64.PubMedCrossRef

Hahner S, Kreissl MC, Fassnacht M, Haenscheid H, Bock S, Verburg FA, et al. Functional characterization of adrenal lesions using [¹²³I]IMTO-SPECT/CT. J Clin Endocrinol Metab. 2013;98:1508–18.PubMedCrossRef

Hahner S, Kreissl MC, Fassnacht M, Haenscheid H, Knoedler P, Lang K, et al. [¹³¹I]iodometomidate for targeted radionuclide therapy of advanced adrenocortical carcinoma. J Clin Endocrinol Metab. 2012;97:914–22.PubMedCrossRef

10.

Modlin IM, Oberg K, Chung DC, Jensen RT, de Herder WW, Thakker RV, et al. Gastroenteropancreatic neuroendocrine tumours. Lancet Oncol. 2008;9:61–72.PubMedCrossRef

11.

Virgolini I, Ambrosini V, Bomanji JB, Baum RP, Fanti S, Gabriel M, et al. Procedure guidelines for PET/CT tumour imaging with ⁶⁸Ga-DOTA-conjugated peptides: ⁶⁸Ga-DOTA-TOC, ⁶⁸Ga-DOTA-NOC, ⁶⁸Ga-DOTA-TATE. Eur J Nucl Med Mol Imaging. 2010;37:2004–10.PubMedCrossRef

12.

Auernhammer CJ, Goke B. Therapeutic strategies for advanced neuroendocrine carcinomas of jejunum/ileum and pancreatic origin. Gut. 2011;60:1009–21.PubMedCrossRef

13.

de Herder WW, Hofland LJ, van der Lely AJ, Lamberts SW. Somatostatin receptors in gastroentero-pancreatic neuroendocrine tumours. Endocr Relat Cancer. 2003;10:451–8.PubMedCrossRef

14.

Bodei L, Mueller-Brand J, Baum RP, Pavel ME, Horsch D, O’Dorisio MS, et al. The joint IAEA, EANM, and SNMMI practical guidance on peptide receptor radionuclide therapy (PRRNT) in neuroendocrine tumours. Eur J Nucl Med Mol Imaging. 2013;40:800–16.PubMedCentralPubMedCrossRef

15.

Krenning EP, Kooij PP, Bakker WH, Breeman WA, Postema PT, Kwekkeboom DJ, et al. Radiotherapy with a radiolabeled somatostatin analogue, [¹¹¹In-DTPA-D-Phe1]-octreotide. A case history. Ann N Y Acad Sci. 1994;733:496–506.PubMedCrossRef

16.

Sundin A. Radiological and nuclear medicine imaging of gastroenteropancreatic neuroendocrine tumours. Best Pract Res Clin Gastroenterol. 2012;26:803–18.PubMedCrossRef

17.

Valkema R, De Jong M, Bakker WH, Breeman WA, Kooij PP, Lugtenburg PJ, et al. Phase I study of peptide receptor radionuclide therapy with [In-DTPA]octreotide: the Rotterdam experience. Semin Nucl Med. 2002;32:110–22.PubMedCrossRef

18.

Anthony LB, Woltering EA, Espenan GD, Cronin MD, Maloney TJ, McCarthy KE. Indium-111-pentetreotide prolongs survival in gastroenteropancreatic malignancies. Semin Nucl Med. 2002;32:123–32.PubMedCrossRef

19.

Kwekkeboom DJ, Krenning EP, Lebtahi R, Komminoth P, Kos-Kudla B, de Herder WW, et al. ENETS consensus guidelines for the standards of care in neuroendocrine tumors: peptide receptor radionuclide therapy with radiolabeled somatostatin analogs. Neuroendocrinology. 2009;90:220–6.PubMedCrossRef

20.

Kowalski J, Henze M, Schuhmacher J, Macke HR, Hofmann M, Haberkorn U. Evaluation of positron emission tomography imaging using [⁶⁸Ga]-DOTA-D Phe(1)-Tyr(3)-Octreotide in comparison to [¹¹¹In]-DTPAOC SPECT. First results in patients with neuroendocrine tumors. Mol Imaging Biol. 2003;5:42–8.PubMedCrossRef

21.

Haug AR, Cindea-Drimus R, Auernhammer CJ, Reincke M, Wangler B, Uebleis C, et al. The role of ⁶⁸Ga-DOTATATE PET/CT in suspected neuroendocrine tumors. J Nucl Med. 2012;53:1686–92.PubMedCrossRef

22.

Ambrosini V, Campana D, Bodei L, Nanni C, Castellucci P, Allegri V, et al. ⁶⁸Ga-DOTANOC PET/CT clinical impact in patients with neuroendocrine tumors. J Nucl Med. 2010;51:669–73.PubMedCrossRef

23.

Otte A, Herrmann R, Heppeler A, Behe M, Jermann E, Powell P, et al. Yttrium-90 DOTATOC: first clinical results. Eur J Nucl Med. 1999;26:1439–47.PubMedCrossRef

24.

Waldherr C, Pless M, Maecke HR, Schumacher T, Crazzolara A, Nitzsche EU, et al. Tumor response and clinical benefit in neuroendocrine tumors after 7.4 GBq (90)Y-DOTATOC. J Nucl Med. 2002;43:610–6.PubMed

25.

Valkema R, Pauwels SA, Kvols LK, Kwekkeboom DJ, Jamar F, de Jong M, et al. Long-term follow-up of renal function after peptide receptor radiation therapy with (90)Y-DOTA(0), Tyr(3)-octreotide and (177)Lu-DOTA(0), Tyr(3)-octreotate. J Nucl Med. 2005;46(Suppl 1):83S–91S.PubMed

26.

Kwekkeboom DJ, de Herder WW, Kam BL, van Eijck CH, van Essen M, Kooij PP, et al. Treatment with the radiolabeled somatostatin analog [¹⁷⁷Lu-DOTA 0, Tyr3]octreotate: toxicity, efficacy, and survival. J Clin Oncol. 2008;26:2124–30.PubMedCrossRef

27.

Van Essen M, Krenning EP, De Jong M, Valkema R, Kwekkeboom DJ. Peptide receptor radionuclide therapy with radiolabelled somatostatin analogues in patients with somatostatin receptor positive tumours. Acta Oncol. 2007;46:723–34.PubMedCrossRef

28.

Sabet A, Haslerud T, Pape UF, Ahmadzadehfar H, Grunwald F, Guhlke S, et al. Outcome and toxicity of salvage therapy with ¹⁷⁷Lu-octreotate in patients with metastatic gastroenteropancreatic neuroendocrine tumours. Eur J Nucl Med Mol Imaging. 2014;41:205–10.PubMedCrossRef

29.

Danthala M, Kallur KG, Prashant GR, Rajkumar K, Raghavendra Rao M. (177)Lu-DOTATATE therapy in patients with neuroendocrine tumours: 5 years experience from a tertiary cancer care centre in India. Eur J Nucl Med Mol Imaging. 2014;41:1319–26.PubMedCrossRef

30.

Sabet A, Ezziddin K, Pape UF, Reichman K, Haslerud T, Ahmadzadehfar H, et al. Accurate assessment of long-term nephrotoxicity after peptide receptor radionuclide therapy with (177)Lu-octreotate. Eur J Nucl Med Mol Imaging. 2014;41:505–10.PubMedCrossRef

31.

Sabet A, Ezziddin K, Pape UF, Ahmadzadehfar H, Mayer K, Poppel T, et al. Long-term hematotoxicity after peptide receptor radionuclide therapy with ¹⁷⁷Lu-octreotate. J Nucl Med. 2013;54:1857–61.PubMedCrossRef

32.

Giovacchini G, Nicolas G, Freidank H, Mindt TL, Forrer F. Effect of amino acid infusion on potassium serum levels in neuroendocrine tumour patients treated with targeted radiopeptide therapy. Eur J Nucl Med Mol Imaging. 2011;38:1675–82.PubMedCrossRef

33.

Kunikowska J, Krolicki L, Hubalewska-Dydejczyk A, Mikolajczak R, Sowa-Staszczak A, Pawlak D. Clinical results of radionuclide therapy of neuroendocrine tumours with ⁹⁰Y-DOTATATE and tandem ⁹⁰Y/¹⁷⁷Lu-DOTATATE: which is a better therapy option? Eur J Nucl Med Mol Imaging. 2011;38:1788–97.PubMedCentralPubMedCrossRef

34.

Haug AR, Auernhammer CJ, Wangler B, Schmidt GP, Uebleis C, Goke B, et al. ⁶⁸Ga-DOTATATE PET/CT for the early prediction of response to somatostatin receptor-mediated radionuclide therapy in patients with well-differentiated neuroendocrine tumors. J Nucl Med. 2010;51:1349–56.PubMedCrossRef

35.

Gabriel M, Decristoforo C, Kendler D, Dobrozemsky G, Heute D, Uprimny C, et al. ⁶⁸Ga-DOTA-Tyr3-octreotide PET in neuroendocrine tumors: comparison with somatostatin receptor scintigraphy and CT. J Nucl Med. 2007;48:508–18.PubMedCrossRef

36.

Elsinga P, Todde S, Penuelas I, Meyer G, Farstad B, Faivre-Chauvet A, et al. Guidance on current good radiopharmacy practice (cGRPP) for the small-scale preparation of radiopharmaceuticals. Eur J Nucl Med Mol Imaging. 2010;37:1049–62.PubMedCentralPubMedCrossRef

37.

Breeman WA, Verbruggen AM. The ⁶⁸Ge/⁶⁸Ga generator has high potential, but when can we use 68 Ga-labelled tracers in clinical routine? Eur J Nucl Med Mol Imaging. 2007;34:978–81.PubMedCentralPubMedCrossRef

38.

Parker D. Tumor Targeting. Chem Br. 1990;26:942–5.

39.

Kwekkeboom DJ, Bakker WH, Kooij PP, Konijnenberg MW, Srinivasan A, Erion JL, et al. [¹⁷⁷Lu-DOTAOTyr3]octreotate: comparison with [111In-DTPAo]octreotide in patients. Eur J Nucl Med. 2001;28:1319–25.PubMedCrossRef

40.

Breeman WA, De Jong M, Visser TJ, Erion JL, Krenning EP. Optimising conditions for radiolabelling of DOTA-peptides with ⁹⁰Y, ¹¹¹In and ¹⁷⁷Lu at high specific activities. Eur J Nucl Med Mol Imaging. 2003;30:917–20.PubMedCrossRef

41.

Das T, Chakraborty S, Banerjee S, Venkatesh M. On the preparation of a therapeutic dose of ¹⁷⁷Lu-labeled DOTA-TATE using indigenously produced ¹⁷⁷Lu in medium flux reactor. Appl Radiat Isot. 2007;65:301–8.PubMedCrossRef

42.

Van Binnebeek S, Baete K, Vanbilloen B, Terwinghe C, Koole M, Mottaghy FM, et al. Individualized dosimetry-based activity reduction of (90)Y-DOTATOC prevents severe and rapid kidney function deterioration from peptide receptor radionuclide therapy. Eur J Nucl Med Mol Imaging. 2014;41:1141–57.PubMed

43.

Van Binnebeek S, Baete K, Terwinghe C, Vanbilloen B, Haustermans K, Mortelmans L, et al. Significant impact of transient deterioration of renal function on dosimetry in PRRT. Ann Nucl Med. 2013;27:74–7.PubMedCrossRef

44.

Helisch A, Forster GJ, Reber H, Buchholz HG, Arnold R, Goke B, et al. Pre-therapeutic dosimetry and biodistribution of ⁸⁶Y-DOTA-Phe1-Tyr3-octreotide versus ¹¹¹In-pentetreotide in patients with advanced neuroendocrine tumours. Eur J Nucl Med Mol Imaging. 2004;31:1386–92.PubMedCrossRef

45.

Stabin MG, Sparks RB, Crowe E. OLINDA/EXM: the second-generation personal computer software for internal dose assessment in nuclear medicine. J Nucl Med. 2005;46:1023–7.PubMed

46.

Göke BFH, Reincke M, Auernhammer CJ. Manual Endokrine Tumore–Empfehlungen zur Diagnostik, Therapie und Nachsorge. 3rd ed. München: W. Zuckschwerdt Verlag; 1998. p.198.

47.

Claringbold PG, Brayshaw PA, Price RA, Turner JH. Phase II study of radiopeptide 177Lu-octreotate and capecitabine therapy of progressive disseminated neuroendocrine tumours. Eur J Nucl Med Mol Imaging. 2011;38:302–11.PubMedCrossRef

48.

Claringbold PG, Price RA, Turner JH. Phase I–II study of radiopeptide ¹⁷⁷Lu-octreotate in combination with capecitabine and temozolomide in advanced low-grade neuroendocrine tumors. Cancer Biother Radiopharm. 2012;27:561–9.PubMedCrossRef

49.

Oddstig J, Bernhardt P, Nilsson O, Ahlman H, Forssell-Aronsson E. Radiation-induced up-regulation of somatostatin receptor expression in small cell lung cancer in vitro. Nucl Med Biol. 2006;33:841–6.PubMedCrossRef

50.

Kennedy A, Coldwell D, Sangro B, Wasan H, Salem R. Integrating radioembolization ((90)Y microspheres) into current treatment options for liver tumors: introduction to the international working group report. Am J Clin Oncol. 2012;35:81–90.PubMedCrossRef

51.

Gupta S, Johnson MM, Murthy R, Ahrar K, Wallace MJ, Madoff DC, et al. Hepatic arterial embolization and chemoembolization for the treatment of patients with metastatic neuroendocrine tumors: variables affecting response rates and survival. Cancer. 2005;104:1590–602.PubMedCrossRef

52.

Ezziddin S, Meyer C, Kahancova S, Haslerud T, Willinek W, Wilhelm K, et al. ⁹⁰Y Radioembolization after radiation exposure from peptide receptor radionuclide therapy. J Nucl Med. 2012;53:1663–9.PubMedCrossRef

53.

Fiore F, Del Prete M, Franco R, Marotta V, Ramundo V, Marciello F, et al. Transarterial embolization (TAE) is equally effective and slightly safer than transarterial chemoembolization (TACE) to manage liver metastases in neuroendocrine tumors. Endocrine. 2014.

54.

Krenning EP, Kwekkeboom DJ, Bakker WH, Breeman WA, Kooij PP, Oei HY, et al. Somatostatin receptor scintigraphy with [¹¹¹In-DTPA-d-Phe1]- and [¹²³I-Tyr3]-octreotide: the Rotterdam experience with more than 1000 patients. Eur J Nucl Med. 1993;20:716–31.PubMedCrossRef

55.

Forrer F, Krenning EP, Kooij PP, Bernard BF, Konijnenberg M, Bakker WH, et al. Bone marrow dosimetry in peptide receptor radionuclide therapy with [¹⁷⁷Lu-DOTA(0), Tyr(3)]octreotate. Eur J Nucl Med Mol Imaging. 2009;36:1138–46.PubMedCentralPubMedCrossRef

56.

Prasad V, Brenner W, Modlin IM. How smart is peptide receptor radionuclide therapy of neuroendocrine tumors especially in the salvage setting? The clinican’s perspective. Eur J Nucl Med Mol Imaging. 2014;41:202–4.PubMedCrossRef

Title: 68Gallium- and 90Yttrium-/177Lutetium: “theranostic twins” for diagnosis and treatment of NETs
Authors: Rudolf A. Werner
Christina Bluemel
Martin S. Allen-Auerbach
Takahiro Higuchi
Ken Herrmann
Publication date: 01-01-2015
Publisher: Springer Japan
Published in: Annals of Nuclear Medicine / Issue 1/2015
Print ISSN: 0914-7187
Electronic ISSN: 1864-6433
DOI: https://doi.org/10.1007/s12149-014-0898-6

Keynote webinar | Spotlight on medication adherence

Springer Medicine

⁶⁸Gallium- and ⁹⁰Yttrium-/¹⁷⁷Lutetium: “theranostic twins” for diagnosis and treatment of NETs

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2015

Assessing margin expansions of internal target volumes in 3D and 4D PET: a phantom study

Distribution of residual long-lived radioactivity in the inner concrete walls of a compact medical cyclotron vault room

Evaluation of normality and reproducibility parameters of scintigraphy with 99mTc-MAA in the diagnosis of intrapulmonary vascular dilatations

Time efficient 124I-PET volumetry in benign thyroid disorders by automatic isocontour procedures: mathematic adjustment using manual contoured measurements in low-dose CT

Comparison of brain perfusion SPECT parameters accuracy for seizure localization in extratemporal lobe epilepsy with discordant pre-surgical data

Definitive chemo-radiotherapy for squamous cell carcinoma of the pharynx: impact of baseline low hemoglobin level (<12 g/dL) and post-radiation therapy F-18 FDG-PET/CT